| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash used in operating activities | -2,084,485 | -1,562,527 |
| Proceeds from the issuance of common stock pursuant to the espp | 63,895 | 24,999 |
| Net cash provided by financing activities | 63,895 | 24,999 |
| Net (decrease) increase in cash and cash equivalents | -2,020,590 | -1,537,528 |
| Cash and cash equivalents at beginning of period | 13,596,600 | - |
| Cash and cash equivalents at end of period | 11,576,010 | - |
Evoke Pharma Inc (EVOK)
Evoke Pharma Inc (EVOK)